A combination of ONCOS-102 plus standard chemotherapy continues to extend the time without disease progression and appears to induce immune system activity in people with malignant pleural mesothelioma unable to undergo surgery, updated results from a Phase 2 clinical trial show. Developed by Targovax, ONCOS-102 is a genetically modified adenovirus designed to infect cancer cells specifically. Once inside these cells, the ONCOS-102 virus produces a protein known as GM-CSF (granulocyte-macrophage-colony-stimulating factor), which stimulates immune system…
You must be logged in to read/download the full post.
The post ONCOS-102 Plus Chemo Showing Sustained Benefit in Mesothelioma Trial appeared first on BioNewsFeeds.